Recent News

• 05.31.2026 - Patient-Reported Outcomes and Health-Related Quality of Life With Taletrectinib in Advanced ROS1+ NSCLC From the TRUST-II Study
• 05.31.2026 - Randomized, Double-Blind, Phase 3 TRUST-IV Study of Adjuvant Taletrectinib vs Placebo in Patients With Stage IB–IIIA ROS1+ Non-Small Cell Lung Cancer (NSCLC)
• 04.21.2026 - Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study
• 04.21.2026 - Taletrectinib in TKI-Naïve Patients With ROS1+ NSCLC: Updated Data From TRUST-I and TRUST-II

Recent Filings

• 05.27.2026 - 8-K Current report
• 05.26.2026 - 4/A Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.04.2026 - EX-99.1 EX-99.1